BASEL, Switzerland, October 29 /PRNewswire/ -- A new study on pain published today has found that subcutaneous (SC) injections of the new renal anaemia therapy MIRCERA is associated with significantly ...
(4) For patients not currently treated with an erythropoiesis stimulating agent (ESA), the recommended starting dose is 0.6 microgram/kg body weight, administered once every two weeks as a single ...
being a common adverse event and a burden for patients with chronic kidney disease (CKD).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback